# Effects of Early Use of Nitazoxanide in Patients With COVID-19

> **NCT04552483** · PHASE2 · COMPLETED · sponsor: **Universidade Federal do Rio de Janeiro** · enrollment: 392 (actual)

## Conditions studied

- Covid19
- Coronavirus

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04552483
- **Lead sponsor:** Universidade Federal do Rio de Janeiro
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-09-05
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552483, "Effects of Early Use of Nitazoxanide in Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04552483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*